Table 1.
Anticytokine therapeutic vaccination
| Cytokine target | Vaccine procedure | Preparation | Therapeutic indication | Refs. |
|---|---|---|---|---|
| Animal experimentation | ||||
| EGF | Active | EGF in CFA | Cancers | 21 |
| IL-1 | Active | PPD–IL-1α | Inflammation | 22 |
| TNF-α | Active | OVA–peptide–TNF-α | Murine polyarthritis | 68, 69 |
| IL-9 | Active | OVA–IL-9 | Murine parasitasis and eosinophilia | 70 |
| IL-4 | Passive | Murine mAb | Allergy to L. major | 73 |
| IL-12 | Passive | Murine mAbs | Colitis | 74 |
| TGF-β | Passive | Monospecific rabbit Abs | Immune-induced lung fibrosis | 75 |
| Clinical trials | ||||
| IFN-α | Active | Inactivated IFN-α | AIDS | 65–67 |
| EGF | Active | Tetanus toxoid–EGF | Colon, lung, stomach, and prostate cancers | 71 |
| IL-4 | Passive | Humanized mAb | Allergy | 76 |
| IL-6 | Passive | mAb | Castleman disease | 77 |
| IL-8 | Passive | Humanized mAb | Psoriasis | 78 |
| TNF-α | Passive | Human, humanized, chimeric mAb | Rheumatoid arthritis, Crohn's disease | 78 |
| VEGF | Passive | Humanized mAb | Colorectal cancer | 78 |
| TGF-β2 | Passive | Human Ab | Glaucoma | 78 |
VEGF, vascular endothelial growth factor.